- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 339/04 - Cycles à cinq chaînons comportant les hétéro-atomes en positions 1, 2, p. ex. acide lipoïque
Détention brevets de la classe C07D 339/04
Brevets de cette classe: 152
Historique des publications depuis 10 ans
|
10
|
9
|
6
|
9
|
10
|
15
|
8
|
5
|
11
|
5
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Cellix Bio Private Limited | 52 |
9 |
| Exerkine Corporation | 34 |
6 |
| Research Foundation of the City University of New York | 421 |
6 |
| Cellixbio Private Limited | 155 |
5 |
| The Government of the United States of America, as represented by the Secretary of the Navy | 1303 |
5 |
| Krisani Biosciences (P) Ltd | 8 |
5 |
| Novartis AG | 10744 |
4 |
| Ischemix LLC | 16 |
4 |
| Antibe Therapeutics Inc. | 21 |
3 |
| Indigene Pharmaceuticals, Inc. | 9 |
3 |
| Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | 58 |
3 |
| Nou-life Sciences, Inc. | 3 |
3 |
| Prous Institute for Biomedical Research, S.A. | 9 |
3 |
| Santen Pharmaceutical Co., Ltd. | 600 |
3 |
| Mitorx Therapeutics Limited | 5 |
3 |
| The United States of America as represented by the Secretary of the Navy | 2753 |
2 |
| The General Hospital Corporation | 4740 |
2 |
| Alnylam Pharmaceuticals, Inc. | 1141 |
2 |
| Cedars-Sinai Medical Center | 1162 |
2 |
| Cyprus University of Technology | 16 |
2 |
| Autres propriétaires | 77 |